CNSP
CNS Pharmaceuticals, Inc. Common Stock
stockNASDAQ
cns pharmaceuticals, inc., a biopharmaceutical company, engages in the development of anti-cancer drug candidates for primary and metastatic cancers of the brain and central nervous system. the company's lead drug candidate is berubicin, which completed phase i clinical trial that is used for the treatment of glioblastoma multiforme. it has license agreements with houston pharmaceuticals, inc. and the university of texas m.d. anderson cancer center; and a development agreement with wpd pharmaceuticals inc. cns pharmaceuticals, inc. was founded in 2017 and is based in houston, texas.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 5.18 | 2026-10-15 | -9.41% | -104.268 |
| 1M | 5.22 | 2026-09-21 | -10.13% | 2.143 |
| 3M | 5.39 | 2026-07-21 | -12.99% | 0.904 |
| 6M | 2.46 | 2026-04-21 | +90.65% | 4.783 |
| 1Y | 9.00 | 2025-10-21 | -47.89% | 1.773 |
| 2Y | 87.60 | 2024-10-21 | -94.65% | — |
| 5Y | 1,287,000.00 | 2021-10-21 | -100.00% | 0.513 |
CNS Pharmaceuticals, Inc. Common Stock (NASDAQ:CNSP) stock price today is $4.69, and today's volume is 288. CNSP is down 0.200% today. The 30 day average volume is 4,687. CNSP market cap is $6.85M with 1.46M shares outstanding.